Erik Phelps Sells 1,302 Shares of Tempus AI (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) EVP Erik Phelps sold 1,302 shares of the company’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $67.42, for a total transaction of $87,780.84. Following the sale, the executive vice president directly owned 89,280 shares of the company’s stock, valued at approximately $6,019,257.60. This trade represents a 1.44% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Erik Phelps also recently made the following trade(s):

• On Tuesday, November 18th, Erik Phelps sold 3,533 shares of Tempus AI stock. The shares were sold at an average price of $65.54, for a total transaction of $231,552.82.

Tempus AI Stock Up 3.6%

Shares of TEM opened at $64.46 on Friday. The firm has a 50 day simple moving average of $77.83 and a two-hundred day simple moving average of $73.65. The company has a debt-to-equity ratio of 2.45, a current ratio of 3.28 and a quick ratio of 3.12. Tempus AI, Inc. has a one year low of $31.36 and a one year high of $104.32. The company has a market cap of $11.47 billion, a P/E ratio of -54.17 and a beta of 4.99.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.05. Tempus AI had a negative return on equity of 73.21% and a negative net margin of 18.45%.The company had revenue of $334.21 million for the quarter, compared to analyst estimates of $328.89 million. During the same quarter last year, the company posted ($0.46) EPS. The company’s revenue for the quarter was up 84.7% compared to the same quarter last year. Research analysts forecast that Tempus AI, Inc. will post -6.15 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. Piper Sandler dropped their target price on shares of Tempus AI from $105.00 to $80.00 and set a “neutral” rating for the company in a report on Tuesday, November 11th. BTIG Research raised their target price on shares of Tempus AI from $96.00 to $105.00 and gave the company a “buy” rating in a research report on Tuesday, November 25th. Guggenheim boosted their target price on shares of Tempus AI from $80.00 to $95.00 and gave the stock a “buy” rating in a research note on Friday, September 26th. TD Cowen downgraded shares of Tempus AI from a “buy” rating to a “hold” rating and set a $88.00 price target for the company. in a report on Tuesday, October 21st. Finally, Morgan Stanley raised their price objective on Tempus AI from $80.00 to $85.00 and gave the company an “overweight” rating in a report on Monday, December 1st. Seven investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $85.36.

Hedge Funds Weigh In On Tempus AI

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Cranbrook Wealth Management LLC acquired a new position in shares of Tempus AI during the third quarter worth $25,000. Concord Wealth Partners raised its position in Tempus AI by 308.0% during the 2nd quarter. Concord Wealth Partners now owns 408 shares of the company’s stock worth $26,000 after purchasing an additional 308 shares during the last quarter. JPL Wealth Management LLC bought a new position in Tempus AI during the 3rd quarter worth $26,000. GAMMA Investing LLC acquired a new position in Tempus AI during the 3rd quarter worth about $28,000. Finally, Allworth Financial LP grew its position in shares of Tempus AI by 5,000.0% in the 2nd quarter. Allworth Financial LP now owns 459 shares of the company’s stock valued at $29,000 after buying an additional 450 shares during the last quarter. 24.22% of the stock is currently owned by institutional investors and hedge funds.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.